clinical trial · NCT06566170
A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease
Eli Lilly and Company·—·recruiting·n = 6,250
Alzheimer DiseaseDonanemabUsual Care
brief summary
The main purpose of this study is to evaluate the long-term effectiveness of donanemab plus usual care versus usual care alone in participants with early symptomatic AD. The study will employ a prospective, observational cohort design with participant management resembling real-world practice to the greatest extent possible via prospective assessments and linkage to historical and prospective electronic health records. The study will last about 273 weeks and may include up to 28 visits.
started
Oct 7, 2024
primary completion
Feb 1, 2033
completion
Feb 1, 2033
last updated
Oct 9, 2025
official title
Long-Term Real-World Comparative Effectiveness of Donanemab Plus Usual Care Versus Usual Care Alone in US Patients With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-REAL US)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol